Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/31322
Type
ArticleCopyright
Open access
Collections
- ENSP - Artigos de Periódicos [2294]
- INI - Artigos de Periódicos [3393]
Metadata
Show full item record
OUTCOMES AMONG HIV-1 INFECTED INDIVIDUALS FIRST STARTING ANTIRETROVIRAL THERAPY WITH CONCURRENT ACTIVE TB OR OTHER AIDS-DEFINING DISEASE
Author
Affilliation
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Departamento de Ciências Biológicas. Rio de Janeiro, RJ, Brasil.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA.
Asociación Civil Impacta Salud y Educación. Lima, Peru.
Frontier Science and Technology Research Foundation. Amherst, NY, USA.
Frontier Science and Technology Research Foundation. Amherst, NY, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil,
Hospital Nossa Senhora da Conceição. Porto Alegre, RS, Brasil.
Kamuzu Central Hospital. Lilongwe, Malawi.
University of Zimbabwe College of Health Sciences. Harare, Zimbabwe.
University of Malawi. College of Medicine. Blantyre, Malawi.
YRG Centre for AIDS Research and Education. Chennai, India.
Nelson R. Mandela School of Medicine. Durban, South Africa.
Brown Medical School. Providence, RI, USA.
University of Colorado. School of Medicine. Department of Medicine. Division of Infectious Diseases. Aurora, CO, USA.
Harvard School of Public Health. Department of Biostatistics. Boston, MA, USA.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, MA, USA.
Asociación Civil Impacta Salud y Educación. Lima, Peru.
Frontier Science and Technology Research Foundation. Amherst, NY, USA.
Frontier Science and Technology Research Foundation. Amherst, NY, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil,
Hospital Nossa Senhora da Conceição. Porto Alegre, RS, Brasil.
Kamuzu Central Hospital. Lilongwe, Malawi.
University of Zimbabwe College of Health Sciences. Harare, Zimbabwe.
University of Malawi. College of Medicine. Blantyre, Malawi.
YRG Centre for AIDS Research and Education. Chennai, India.
Nelson R. Mandela School of Medicine. Durban, South Africa.
Brown Medical School. Providence, RI, USA.
University of Colorado. School of Medicine. Department of Medicine. Division of Infectious Diseases. Aurora, CO, USA.
Harvard School of Public Health. Department of Biostatistics. Boston, MA, USA.
Abstract
Tuberculosis (TB) is common among HIV-infected individuals in many resource-limited countries and has been associated with poor survival. We evaluated morbidity and mortality among individuals first starting antiretroviral therapy (ART) with concurrent active TB or other AIDS-defining disease using data from the "Prospective Evaluation of Antiretrovirals in Resource-Limited Settings" (PEARLS) study.
Share